Trials / Completed
CompletedNCT00144456
A New Active Vitamin D, ED-71 for Osteoporosis
A Prospective, Randomized, Double-blind Study to Compare the Effect of ED-71 With That of Alfacalcidol on Fracture Incidence in Osteoporotic Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,056 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
A prospective, randomized, double-blind study to compare the effect of ED-71 with that of alfacalcidol on fracture incidence
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ED-71 | 0.75μg/day(p.o.)for 144 weeks |
| DRUG | Alfacalcidol | 1.0μg/day(p.o.)for 144 weeks |
| DRUG | ED-71 placebo | 0 μg/day(p.o.)for 144 weeks |
| DRUG | Alfacalcidol placebo | 0 μg/day(p.o.)for 144 weeks |
Timeline
- Start date
- 2004-09-01
- Primary completion
- 2008-09-01
- Completion
- 2008-10-01
- First posted
- 2005-09-05
- Last updated
- 2013-08-09
Source: ClinicalTrials.gov record NCT00144456. Inclusion in this directory is not an endorsement.